July 17, 2018
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.
May 10, 2018
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
May 1, 2018
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
March 28, 2018
Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.
March 13, 2018
The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.
January 2, 2018
Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.
October 3, 2017
The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.
June 7, 2017
New “CRO Finder” Connects Scientists with Specialized Resources
January 18, 2017
ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
May 13, 2016
The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.